moxifloxacin has been researched along with allopurinol in 7 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (allopurinol) | Trials (allopurinol) | Recent Studies (post-2010) (allopurinol) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 15,096 | 743 | 3,363 |
| Protein | Taxonomy | moxifloxacin (IC50) | allopurinol (IC50) |
|---|---|---|---|
| Xanthine dehydrogenase/oxidase [Includes: Xanthine dehydrogenase | Rattus norvegicus (Norway rat) | 3.3765 | |
| Xanthine dehydrogenase/oxidase | Homo sapiens (human) | 3.1861 | |
| Xanthine dehydrogenase/oxidase | Bos taurus (cattle) | 5.0758 | |
| Histamine H3 receptor | Cavia porcellus (domestic guinea pig) | 8.69 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fujita, T; Hashimoto, H; Kumagai, Y; Nakamura, Y; Sugiyama, A | 1 |
| Bjursell, M; Dota, C; Gottfridsson, C; Johansson, S; Källgren, C; Kӧrnicke, T; Parkinson, J; Perl, S; Rekić, D | 1 |
1 review(s) available for moxifloxacin and allopurinol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for moxifloxacin and allopurinol
| Article | Year |
|---|---|
QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation.
Topics: Adult; Asian People; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Nitriles; Pyridines; Xanthine Oxidase; Young Adult | 2014 |
Verinurad does not prolong QTc interval: a thorough QT study using concentration-QTc modelling.
Topics: Allopurinol; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Heart Rate; Humans; Long QT Syndrome; Moxifloxacin; Uric Acid | 2023 |
4 other study(ies) available for moxifloxacin and allopurinol
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |